Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn’s Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature

Use of ustekinumab in Crohn’s disease was approved in 2016, and consequently data regarding its real-world safety are still limited. We here present a 29-year-old woman with severe therapy-refractory Crohn’s disease, who developed an anaplastic large cell T cell lymphoma during treatment with usteki...

Descripción completa

Detalles Bibliográficos
Autores principales: Smeets, Fabiënne G M, Liedorp, Paulien R, van der Poel, Marjolein, Miclea, Razvan L, Masclee, Ad A M, Pierik, Marieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142401/
https://www.ncbi.nlm.nih.gov/pubmed/31116402
http://dx.doi.org/10.1093/ecco-jcc/jjz084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142401/
https://www.ncbi.nlm.nih.gov/pubmed/31116402
http://dx.doi.org/10.1093/ecco-jcc/jjz084

Ejemplares similares